| |
From risk mitigation to program-level country and site strategy, IQVIA helped help this sponsor prove operational feasibility for six concurrent global studies. Download the case study.
|
|
|
Wednesday, Jun 14, 2023 | 10:00am ET / 7:00am PT Targeting proteins for degradation therapeutically, as an alternative to inhibiting them, holds great promise for treating diseases in which pathogenic proteins are considered "undruggable" due to a lack of active sites for conventional small molecules. Register now.
|
|
| By Gabrielle Masson As usual, ASCO occurred the first weekend in June in Chicago. Except this year, a superstar whose reputation precedes her put on a rivaling show right next door. |
|
|
|
By Zoey Becker Eisai was the victim of a ransomware attack late Saturday night and is now working on response efforts, including the creation of a company-wide task force. |
By Angus Liu As doctors navigate the "messy" early-stage non-small cell lung cancer landscape with various immunotherapy approaches, Merck & Co. has now unveiled new data that it hopes can establish Keytruda, used before and after surgery, as a new standard of care. |
By Gabrielle Masson Johnson & Johnson has seen response rates as high as 97% in multiple myeloma before but this time, it’s not for Carvykti. No, this time the healthcare giant’s pharmaceutical unit Janssen is shining the spotlight on a combo study for talquetamab and Tecvayli. |
By Zoey Becker After spinning off from Novartis later this year, generics and biosimilars giant Sandoz plans to move into its new headquarters by the middle of 2024. |
By James Waldron Easing pain may have been one of the original goals of medicine, but the zeitgeist has long since moved on to harder-to-treat conditions. That makes Eli Lilly’s efforts to reinvigorate the space all the more intriguing. |
By Andrea Park Hundreds of people who used Grail’s Galleri multicancer blood test reportedly received letters last month incorrectly indicating that they might have cancer. |
By Nick Paul Taylor BioNTech has shared an updated look at the data that persuaded it to gamble $200 million on a rival to Bristol Myers Squibb’s Yervoy. The phase 1/2 study linked the anti-CTLA-4 antibody to a 29.6% response rate, offering encouragement to BioNTech and partner OncoC4 as they gear up for a pivotal clinical trial. |
By Max Bayer “It's a good time to be investing in and acquiring innovation,” Jazz Pharmaceuticals CEO Bruce Cozadd says, as the company scouts for deals at the BIO International Convention. |
By Andrea Park Study results that Novocure presented at the American Society of Clinical Oncology annual meeting Tuesday scratched a seven-year itch: According to the company, it's the first phase 3 clinical trial in at least as long to detail a therapy’s ability to significantly improve the survival rate for patients with platinum-resistant, metastatic non-small cell lung cancer. |
By Zoey Becker The Centers for Medicare and Medicaid Services has said it plans to cover Alzheimer's disease meds with the use of a registry to collect real-world data from physicians. Trade group PhRMA argues the move will "severely restrict" access. |
By Andrea Park The new additions bring the total number of complaints that the FDA has collected between April 2021—when Philips first began alerting customers to potential issues with some of its respiratory devices—and the end of March of this year to more than 105,000, with 385 reported deaths. |
By Angus Liu Novartis has pulled back the curtains on the highly anticipated Kisqali data that previously drove an 8% share-price rally in a single day. As the Swiss pharma aims to bring the CDK4/6 battle with Eli Lilly into earlier treatment of breast cancer, the trial results indicate there's an intense rivalry ahead. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Executive SummaryTraditional real-world data isn’t truly from the real world – it’s from the clinical world, and it’s missing a big part of neuro patients’ stories. Sponsored by: Evidation Health |
| WhitepaperBuilding a Sustainable Blueprint for a Holistic Market Access Strategy Sponsored by: EVERSANA® |
| Whitepaper Modern software development and its impact on addressing clinical trial complexity. Sponsored by: YPrime |
| WhitepaperDrive brand growth with proven digital strategies to accelerate and optimize all lifecycle stages including drug discovery, launch, maturity and LoE. Sponsored by: LiveWorld full-service digital agency with deep social expertise |
| ResearchThere’s a $70 billion growth opportunity for pharma and medtech in transitioning care from the hospital to home. Read our latest report to find out how we can create better patient outcomes and drive health equity. Sponsored by: PA Consulting |
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
